Study of LYL314 in Aggressive Large B-Cell Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

May 9, 2023

Primary Completion Date

December 31, 2028

Study Completion Date

June 30, 2031

Conditions
Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon-Hodgkin LymphomaLarge B-cell Lymphoma
Interventions
DRUG

LYL314

CAR T-cell therapy

DRUG

Fludarabine

Conditioning chemotherapy

DRUG

Cyclophosphamide

Conditioning chemotherapy

Trial Locations (20)

10461

RECRUITING

Montefiore Medical Center, The Bronx

18103

RECRUITING

Lehigh Valley Topper Cancer Center Institute, Allentown

19107

RECRUITING

Thomas Jefferson University, Philadelphia

23298

RECRUITING

Virginia Commonwealth University-Massey Cancer Center, Richmond

30912

RECRUITING

Augusta University Medical Center, Augusta

40202

RECRUITING

University of Louisville Brown Cancer Center, Louisville

45267

RECRUITING

University of Cincinnati (UC) Physicians Company, LLC, Cincinnati

46237

RECRUITING

Indiana Blood and Marrow Transplantation, Indianapolis

49503

RECRUITING

Corewell Health, Grand Rapids

52242

RECRUITING

University of Iowa, Iowa City

53226

RECRUITING

Medical College of Wisconsin, Milwaukee

75246

RECRUITING

Baylor University Medical Center, Dallas

80218

RECRUITING

Colorado Blood Cancer Institute, Denver

84112

RECRUITING

Huntsman Cancer Institute, Salt Lake City

84143

RECRUITING

Intermountain Healthcare, Salt Lake City

87131

RECRUITING

University of New Mexico Comprehensive Cancer Center, Albuquerque

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

90095

RECRUITING

University of California, Los Angeles (UCLA) Medical Center, Los Angeles

92037

RECRUITING

Scripps Clinic, San Diego

92697

RECRUITING

University of California-Irvine Medical Center, Irvine

Sponsors
All Listed Sponsors
lead

Lyell Immunopharma, Inc.

INDUSTRY